{"id":389359,"date":"2020-11-30T07:03:40","date_gmt":"2020-11-30T12:03:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=389359"},"modified":"2020-11-30T07:03:40","modified_gmt":"2020-11-30T12:03:40","slug":"cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/","title":{"rendered":"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer"},"content":{"rendered":"
\n

Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n CAMBRIDGE, Mass.<\/span>, Nov. 30, 2020<\/span> \/PRNewswire\/ —\u00a0Cogent Biosciences, Inc.\u00a0(“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Brad Barnett\u00a0as Chief Technology Officer (CTO). In his new role,\u00a0Mr. Barnett will\u00a0be responsible for all aspects of chemistry, manufacturing and controls (CMC),\u00a0technical development, supply chain operations,\u00a0and alliance management. <\/p>\n

\n

\n
\n \"\"
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“We are excited to welcome Brad to the growing Cogent Biosciences team. Brad’s\u00a0extensive experience leading the manufacturing\u00a0and supply chain organization\u00a0at Array BioPharma will prove\u00a0invaluable as we expand PLX9486 into clinical trials for systemic mastocytosis and gastrointestinal stromal tumor (GIST)\u00a0patients,” said Andrew Robbins<\/span>, President & CEO of Cogent Biosciences. “I had the pleasure of working with Brad at Array,\u00a0and I am excited to reconnect\u00a0as we execute on our development plans\u00a0for PLX9486. Additionally, Brad will be a great asset to our team as we look to the future\u00a0of the company including building a portfolio of new, selective, and potent precision medicines around our lead asset PLX9486.”<\/p>\n

Mr. Barnett is a deeply experienced technical operations executive with a\u00a0demonstrated knowledge of the pharmaceutical industry. His extensive career includes\u00a0nearly 20\u00a0years at Array BioPharma where he most recently served as Vice President of Supply Chain & Manufacturing. Mr. Barnett joined Array in 2000, two years after the company was founded, and played an invaluable role in successfully bringing Mektovi and Braftovi, two precision oncology medicines, to market while serving in a range of roles including\u00a0research, business development and technical operations. Prior to joining Cogent, he led the Mektovi and Braftovi manufacturing integration into Pfizer following Pfizer’s acquisition of Array.\u00a0Mr. Barnett holds an MBA from the University of Colorado<\/span>, and a B.S. in Chemistry from Colorado State University<\/span>.<\/p>\n

\n About\u00a0<\/b>
\n Cogent Biosciences, Inc.<\/b>
\n
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA.<\/span> Visit our website for more information at www.cogentbio.com<\/a>. Follow Cogent Biosciences on social media: Twitter<\/a>\u00a0and LinkedIn.<\/a><\/p>\n

\n Forward Looking Statements<\/b>\n <\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: projected cash runways; future product development plans; upcoming results from clinical trials including from its lead program, PLX9486. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in Cogent’s most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.<\/p>\n

\n Media Contact
<\/b>
\n Amanda Sellers<\/span>
\n
\n asellers@vergescientific.com<\/a>
\n
301.332.5574<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Cogent
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer-301181522.html<\/a><\/p>\n

SOURCE Cogent Biosciences, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing PR Newswire CAMBRIDGE, Mass., Nov. 30, 2020 \/PRNewswire\/ —\u00a0Cogent Biosciences, Inc.\u00a0(“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Brad Barnett\u00a0as Chief Technology Officer (CTO). In his new role,\u00a0Mr. Barnett will\u00a0be responsible for all aspects of chemistry, manufacturing and controls (CMC),\u00a0technical development, supply chain operations,\u00a0and alliance management. “We are excited to welcome Brad to the growing Cogent Biosciences team. Brad’s\u00a0extensive experience leading the manufacturing\u00a0and supply chain organization\u00a0at Array BioPharma will prove\u00a0invaluable as we expand PLX9486 into clinical trials for systemic mastocytosis and gastrointestinal stromal … <\/p>\n

Continue reading “Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-389359","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCogent Biosciences Appoints Brad Barnett as Chief Technology Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing PR Newswire CAMBRIDGE, Mass., Nov. 30, 2020 \/PRNewswire\/ —\u00a0Cogent Biosciences, Inc.\u00a0(“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Brad Barnett\u00a0as Chief Technology Officer (CTO). In his new role,\u00a0Mr. Barnett will\u00a0be responsible for all aspects of chemistry, manufacturing and controls (CMC),\u00a0technical development, supply chain operations,\u00a0and alliance management. “We are excited to welcome Brad to the growing Cogent Biosciences team. Brad’s\u00a0extensive experience leading the manufacturing\u00a0and supply chain organization\u00a0at Array BioPharma will prove\u00a0invaluable as we expand PLX9486 into clinical trials for systemic mastocytosis and gastrointestinal stromal … Continue reading "Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T12:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1344623\/Brad_Barnett.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer\",\"datePublished\":\"2020-11-30T12:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/\"},\"wordCount\":783,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1344623\\\/Brad_Barnett.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/\",\"name\":\"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1344623\\\/Brad_Barnett.jpg\",\"datePublished\":\"2020-11-30T12:03:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1344623\\\/Brad_Barnett.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1344623\\\/Brad_Barnett.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/","og_locale":"en_US","og_type":"article","og_title":"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer - Market Newsdesk","og_description":"Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing PR Newswire CAMBRIDGE, Mass., Nov. 30, 2020 \/PRNewswire\/ —\u00a0Cogent Biosciences, Inc.\u00a0(“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Brad Barnett\u00a0as Chief Technology Officer (CTO). In his new role,\u00a0Mr. Barnett will\u00a0be responsible for all aspects of chemistry, manufacturing and controls (CMC),\u00a0technical development, supply chain operations,\u00a0and alliance management. “We are excited to welcome Brad to the growing Cogent Biosciences team. Brad’s\u00a0extensive experience leading the manufacturing\u00a0and supply chain organization\u00a0at Array BioPharma will prove\u00a0invaluable as we expand PLX9486 into clinical trials for systemic mastocytosis and gastrointestinal stromal … Continue reading \"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T12:03:40+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1344623\/Brad_Barnett.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer","datePublished":"2020-11-30T12:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/"},"wordCount":783,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1344623\/Brad_Barnett.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/","name":"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1344623\/Brad_Barnett.jpg","datePublished":"2020-11-30T12:03:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1344623\/Brad_Barnett.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1344623\/Brad_Barnett.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-appoints-brad-barnett-as-chief-technology-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=389359"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/389359\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=389359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=389359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=389359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}